Pheochromocytoma and Paraganglioma in the Pediatric Population

  • Rachel Kadakia
  • Monica Bianco
  • Elizabeth Dabrowski
  • Donald Zimmerman
Part of the Contemporary Endocrinology book series (COE)


Pheochromocytomas and paragangliomas are rare tumors in the pediatric population that arise from neural crest cells. Prompt recognition and treatment are necessary to limit morbidity. Compared to adults, pheochromocytoma and paraganglioma in children are more likely to be associated with an underlying genetic syndrome, and genetic testing should be pursued. These tumors can produce catecholamines and present with symptoms such as sweating, nausea, emesis, hypertension, or diarrhea, or they can be nonfunctional and present with symptoms related to mass effect. Evaluation is initiated with measurement of urine and plasma metanephrines and diagnosis confirmed with magnetic resonance imaging. Definitive treatment occurs via surgical excision. A multidisciplinary team specifically trained in the management of pediatric PHEO and PGL is necessary for optimal patient care.


Pheochromocytoma Paraganglioma Catecholamine Multiple endocrine neoplasia Familial PGL syndrome Von Hippel-Lindau syndrome 


  1. 1.
    Beltsevich DG, Kuznetsov NS, Kazaryan AM, Lysenko MA. Pheochromocytoma surgery: epidemiologic peculiarities in children. World J Surg. 2004;28(6):592–6.CrossRefGoogle Scholar
  2. 2.
    Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci. 2006;1073:30–7.CrossRefGoogle Scholar
  3. 3.
    Waguespack SG, Rich T, Grubbs E, et al. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2010;95(5):2023–37.CrossRefGoogle Scholar
  4. 4.
    Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459–66.CrossRefGoogle Scholar
  5. 5.
    Babic B, Patel D, Aufforth R, et al. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. Surgery. 2017;161(1):220–7.CrossRefGoogle Scholar
  6. 6.
    Pamporaki C, Hamplova B, Peitzsch M, et al. Characteristics of Pediatric vs adult Pheochromocytomas and Paragangliomas. J Clin Endocrinol Metab. 2017;102(4):1122–32.CrossRefGoogle Scholar
  7. 7.
    Wyszynska T, Cichocka E, Wieteska-Klimczak A, Jobs K, Januszewicz PA. Single pediatric center experience with 1025 children with hypertension. Acta Paediatr (Oslo, Norway : 1992). 1992;81(3):244–6.CrossRefGoogle Scholar
  8. 8.
    Grinsell MM, Norwood VF. At the bottom of the differential diagnosis list: unusual causes of pediatric hypertension. Pediatr Nephrol (Berlin, Germany). 2009;24(11):2137–46.CrossRefGoogle Scholar
  9. 9.
    Pham TH, Moir C, Thompson GB, et al. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. Pediatrics. 2006;118(3):1109–17.CrossRefGoogle Scholar
  10. 10.
    Sullivan J, Groshong T, Tobias JD. Presenting signs and symptoms of pheochromocytoma in pediatric-aged patients. Clin Pediatr. 2005;44(8):715–9.CrossRefGoogle Scholar
  11. 11.
    Bausch B, Wellner U, Bausch D, et al. Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer. 2014;21(1):17–25.CrossRefGoogle Scholar
  12. 12.
    Barontini M, Dahia PL. VHL disease. Best Pract Res Clin Endocr Metab. 2010;24(3):401–13.CrossRefGoogle Scholar
  13. 13.
    Aufforth RD, Ramakant P, Sadowski SM, et al. Pheochromocytoma screening initiation and frequency in von Hippel-Lindau syndrome. J Clin Endocrinol Metab. 2015;100(12):4498–504.CrossRefGoogle Scholar
  14. 14.
    Glasker S, Neumann HPH, Koch CA, Vortmeyer AO. Von Hippel-Lindau disease. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext. South Dartmouth:, Inc.; 2000.Google Scholar
  15. 15.
    Kirmani S, Young WF. Hereditary paraganglioma-pheochromocytoma syndromes. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews(R). Seattle: University of Washington, Seattle University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved; 1993.Google Scholar
  16. 16.
    Gruber LM, Erickson D, Babovic-Vuksanovic D, Thompson GB, Young WF Jr, Bancos I. Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1. Clin Endocrinol. 2017;86(1):141–9.CrossRefGoogle Scholar
  17. 17.
    Bausch B, Borozdin W, Clinical NHP. Genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med. 2006;354(25):2729–31.CrossRefGoogle Scholar
  18. 18.
    Marquard J, Eng C. Multiple endocrine neoplasia type 2. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews(R). Seattle: University of Washington, Seattle University of Washington, Seattle. All rights reserved; 1993.Google Scholar
  19. 19.
    Pacak K, Ilias I, Adams KT, Eisenhofer G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med. 2005;257(1):60–8.CrossRefGoogle Scholar
  20. 20.
    Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto- oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575–9.CrossRefGoogle Scholar
  21. 21.
    Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42.CrossRefGoogle Scholar
  22. 22.
    Weismann D, Peitzsch M, Raida A, et al. Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. Eur J Endocrinol. 2015;172(3):251–60.CrossRefGoogle Scholar
  23. 23.
    Parra A, Ramirez del Angel A, Cervantes C, Sanchez M. Urinary excretion of catecholamines in healthy subjects in relation to body growth. Acta Endocrinol. 1980;94(4):546–51.PubMedGoogle Scholar
  24. 24.
    Weise M, Merke DP, Pacak K, Walther MM, Eisenhofer G. Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metab. 2002;87(5):1955–60.CrossRefGoogle Scholar
  25. 25.
    Grossrubatscher E, Dalino P, Vignati F, et al. The role of chromogranin a in the management of patients with phaeochromocytoma. Clin Endocrinol. 2006;65(3):287–93.CrossRefGoogle Scholar
  26. 26.
    Bilek R, Safarik L, Ciprova V, Vlcek P, Lisa L, Chromogranin A. A member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma. Physiol Res. 2008;57(Suppl 1):S171–9.PubMedGoogle Scholar
  27. 27.
    Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14(3):569–85.CrossRefGoogle Scholar
  28. 28.
    Hack HA. The perioperative management of children with phaeochromocytoma. Paediatr Anaesth. 2000;10(5):463–76.CrossRefGoogle Scholar
  29. 29.
    Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92(11):4069–79.CrossRefGoogle Scholar
  30. 30.
    Ludwig AD, Feig DI, Brandt ML, Hicks MJ, Fitch ME, Cass DL. Recent advances in the diagnosis and treatment of pheochromocytoma in children. Am J Surg. 2007;194(6):792–6. discussion 796–7CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Rachel Kadakia
    • 1
    • 2
  • Monica Bianco
    • 1
    • 2
  • Elizabeth Dabrowski
    • 1
    • 2
  • Donald Zimmerman
    • 1
    • 2
  1. 1.Department of PediatricsNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Division of EndocrinologyAnn and Robert H. Lurie Children’s Hospital of ChicagoChicagoUSA

Personalised recommendations